Henry Meds vs Ivim Health: How Each Dispenses GLP-1 Meds

This article is part of the PlexusDx Education Hub, a library of evidence-based guidance on GLP-1 therapies, weight-management protocols, and the genetic factors that shape metabolic care. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no commercial relationship with Henry Meds or Ivim Health and includes no affiliate links or paid placement.

Full head-to-head: PlexusDx vs Henry Meds →

When people search Henry Meds versus Ivim Health, the "meds" in the query is the point: they want to understand how each program actually handles the medication. Both run telehealth alongside a compounded-pharmacy pathway, so this comparison leads with dispensing, the 503A route, and what branded-versus-compounded really means, then closes on the genetic input that sits above the medication itself. As of April 2026.

How Henry Meds handles the medication

Henry Meds pairs telehealth with a compounded-pharmacy pathway. A licensed provider reviews the intake and can prescribe a branded FDA-approved GLP-1 or compounded semaglutide or tirzepatide fulfilled through a licensed pharmacy. The medication side of the program, including which products are stocked, is documented on the Henry Meds website.

How Ivim Health handles the medication

Ivim Health also combines telehealth with a compounded-pharmacy pathway, routing prescriptions to a retail pharmacy for branded products or to a 503A compounding pharmacy for compounded semaglutide or tirzepatide. The medication lineup and dispensing specifics live on the Ivim Health website and shift with supply.

Compounded versus branded: what the 503A pathway means

A 503A compounding pharmacy prepares a medication for an individual patient under a prescription, which is a different regulatory lane from a mass-manufactured branded product. Both Henry Meds and Ivim Health may use compounded semaglutide or tirzepatide, so the practical questions are which pharmacy partners each uses and whether you receive a branded or compounded formulation.

Why the molecule, not the platform, drives results

However the medication is dispensed, its behavior comes from the compound. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 agonist tirzepatide act on appetite and satiety with trial support from STEP (NEJM 2021), SURMOUNT (NEJM 2022), and SURMOUNT-OSA (NEJM 2024). The dispensing platform changes logistics, not pharmacology.

Questions worth asking about the pharmacy

Since both programs lean on pharmacy partners, the medication questions that matter are practical. Ask which pharmacies fulfill the prescription, whether you will receive a branded or compounded formulation, how the product is shipped and stored, and how refills are timed against your titration schedule. A program that answers these clearly is easier to trust than one that treats the pharmacy as a black box, and the answers often reveal more about day-to-day experience than the headline price does.

The genetic input missing from both programs

Neither dispensing model reads the biology the medication enters. A variant in FTO, the fat-mass and obesity-associated gene, plus GLP1R and TCF7L2, describes the metabolic baseline any compounded or branded GLP-1 acts on. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights across that terrain, and it never predicts how you will respond to a particular medication.

How PlexusDx pairs medication with genetics

PlexusDx dispenses semaglutide and tirzepatide through its Weight Management Protocols, offered as Semaglutide Injection ($189/month), Semaglutide Oral, Tirzepatide Injection ($289/month), and Tirzepatide Oral. The Precision Peptide Genetic Test pairs the medication with the genetic context most dispensing-focused programs skip.

Not affiliated: PlexusDx has no commercial relationship with Henry Meds, Ivim Health, or any brand named in this comparison.

Keep reading on PlexusDx: GLP-1 Drugs, GLP-1 Hormone, What Is GLP-1, GLP-1 What Is.

Editorial note: this comparison is educational. PlexusDx sells semaglutide and tirzepatide through its own Weight Management Protocols and is not affiliated with the reviewed brands. The Precision Peptide Genetic Test reports genetic influence on peptide pathways and does not predict medication response. Talk with a qualified provider before beginning a protocol.

Frequently Asked Questions

Do Henry Meds and Ivim Health dispense compounded or branded medication?

Both can do either, depending on eligibility and supply. Prescriptions may route to a retail pharmacy for a branded FDA-approved GLP-1 or to a 503A compounding pharmacy for compounded semaglutide or tirzepatide. Check each brand current catalog to see which formulation you would actually receive.

What is a 503A compounding pharmacy?

A 503A pharmacy prepares a medication for an individual patient under a specific prescription, a different regulatory pathway from mass-manufactured branded drugs. It is a legitimate route used across telehealth GLP-1 programs, and both services reviewed here rely on licensed pharmacy partners for fulfillment.

Does the compounded version work differently from branded?

The active compound, semaglutide or tirzepatide, is the same molecule whether branded or compounded, so the pharmacology is not changed by the dispensing route. Differences to weigh are formulation specifics, pharmacy quality, and cost, which is why verifying the pharmacy partner matters.

Where does genetic testing fit into the medication decision?

Genetic testing sits above the medication choice. The Precision Peptide Genetic Test maps variants such as FTO that describe your baseline metabolic biology, context that stays relevant whether you receive a branded or compounded GLP-1 from either program.

This article belongs to the PlexusDx Education Hub. Browse all Peptides & GLP-1 education